A sensor array has the potential to identify de novo Parkinson's disease (PD) patients with high sensitivity, specificity, and accuracy values.
The studies that included neurocognitive measures demonstrated no significant difference between the use of rTMS and sham-rTMS.
Mutations in the LRP10 gene appear to be common in patients with inherited α-synucleinopathies.
Investigators sought to determine whether patients with moderate to advanced Parkinson disease have impaired glucose levels during an Oral Glucose Tolerance Test.
Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.
Using information from these assessments, investigators identified participants as having either major psychotic symptoms, isolated minor psychotic symptoms, or no psychotic symptoms.
Researchers conducted a multicenter study to assess the predictive value of the Montreal Parkinson Risk of Dementia Scale, an 8-item, office-based screening tool.
Investigators analyzed data for baseline factors that may influence weight loss in early parkinson's disease.
Neurology Advisor Articles
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease
- Scribes Improve Physician Workflow, Patient Interaction